Zoetis Inc. (0M3Q.L)
USD 147.42
(-3.98%)
USD 147.42
(-3.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.76 Billion USD | 5.52% |
| 2022 | 4.51 Billion USD | 38.39% |
| 2021 | 3.26 Billion USD | -13.27% |
| 2020 | 3.76 Billion USD | -19.64% |
| 2019 | 4.67 Billion USD | -3.53% |
| 2018 | 4.85 Billion USD | 43.11% |
| 2017 | 3.38 Billion USD | -9.41% |
| 2016 | 3.74 Billion USD | 0.73% |
| 2015 | 3.71 Billion USD | 34.18% |
| 2014 | 2.76 Billion USD | -9.16% |
| 2013 | 3.04 Billion USD | 1049.81% |
| 2012 | 265 Million USD | -46.57% |
| 2011 | 496 Million USD | -23.46% |
| 2010 | 648 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 5.04 Billion USD | -2.5% |
| 2024 Q2 | 5.17 Billion USD | 7.82% |
| 2024 Q1 | 4.79 Billion USD | 0.69% |
| 2023 Q4 | 4.76 Billion USD | -4.65% |
| 2023 FY | 4.76 Billion USD | 5.52% |
| 2023 Q2 | 5.03 Billion USD | 8.5% |
| 2023 Q3 | 4.99 Billion USD | -0.74% |
| 2023 Q1 | 4.63 Billion USD | 2.75% |
| 2022 Q4 | 4.51 Billion USD | 6.29% |
| 2022 FY | 4.51 Billion USD | 38.39% |
| 2022 Q2 | 4.08 Billion USD | 13.47% |
| 2022 Q1 | 3.6 Billion USD | 10.43% |
| 2022 Q3 | 4.24 Billion USD | 3.92% |
| 2021 Q2 | 3.68 Billion USD | -1.68% |
| 2021 Q3 | 3.47 Billion USD | -5.62% |
| 2021 FY | 3.26 Billion USD | -13.27% |
| 2021 Q1 | 3.74 Billion USD | -0.32% |
| 2021 Q4 | 3.26 Billion USD | -6.24% |
| 2020 Q4 | 3.76 Billion USD | -10.67% |
| 2020 FY | 3.76 Billion USD | -19.64% |
| 2020 Q1 | 4.67 Billion USD | -0.17% |
| 2020 Q2 | 4.49 Billion USD | -3.73% |
| 2020 Q3 | 4.2 Billion USD | -6.4% |
| 2019 Q4 | 4.67 Billion USD | -2.62% |
| 2019 Q1 | 4.85 Billion USD | 0.0% |
| 2019 Q2 | 4.86 Billion USD | 0.29% |
| 2019 Q3 | 4.8 Billion USD | -1.21% |
| 2019 FY | 4.67 Billion USD | -3.53% |
| 2018 Q4 | 4.85 Billion USD | -5.92% |
| 2018 FY | 4.85 Billion USD | 43.11% |
| 2018 Q3 | 5.15 Billion USD | 51.75% |
| 2018 Q2 | 3.39 Billion USD | 2.94% |
| 2018 Q1 | 3.3 Billion USD | -2.63% |
| 2017 Q3 | 3.72 Billion USD | -3.7% |
| 2017 FY | 3.38 Billion USD | -9.41% |
| 2017 Q2 | 3.86 Billion USD | 0.65% |
| 2017 Q1 | 3.83 Billion USD | 2.62% |
| 2017 Q4 | 3.38 Billion USD | -8.92% |
| 2016 FY | 3.74 Billion USD | 0.73% |
| 2016 Q1 | 3.79 Billion USD | 2.13% |
| 2016 Q3 | 3.81 Billion USD | 0.13% |
| 2016 Q2 | 3.81 Billion USD | 0.47% |
| 2016 Q4 | 3.74 Billion USD | -1.97% |
| 2015 FY | 3.71 Billion USD | 34.18% |
| 2015 Q2 | 3.1 Billion USD | 0.55% |
| 2015 Q4 | 3.71 Billion USD | 22.09% |
| 2015 Q3 | 3.04 Billion USD | -1.97% |
| 2015 Q1 | 3.08 Billion USD | 11.49% |
| 2014 Q1 | 3.15 Billion USD | 3.45% |
| 2014 Q2 | 3.07 Billion USD | -2.41% |
| 2014 Q3 | 3.05 Billion USD | -0.72% |
| 2014 Q4 | 2.76 Billion USD | -9.36% |
| 2014 FY | 2.76 Billion USD | -9.16% |
| 2013 FY | 3.04 Billion USD | 1049.81% |
| 2013 Q1 | 3.17 Billion USD | 1099.25% |
| 2013 Q2 | 3.28 Billion USD | 3.3% |
| 2013 Q3 | 3.26 Billion USD | -0.61% |
| 2013 Q4 | 3.04 Billion USD | -6.62% |
| 2012 Q4 | 265 Million USD | -40.72% |
| 2012 Q2 | 467 Million USD | 0.21% |
| 2012 Q3 | 447 Million USD | -4.28% |
| 2012 FY | 265 Million USD | -46.57% |
| 2012 Q1 | 466 Million USD | -6.05% |
| 2011 FY | 496 Million USD | -23.46% |
| 2011 Q4 | 496 Million USD | 0.0% |
| 2010 FY | 648 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 4725.501% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 15354.509% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -2304.261% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -14834.922% |
| bluebird bio, Inc. | 108.57 Million USD | -4286.07% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 52917.214% |
| Imunon, Inc. | -4.69 Million USD | 101434.823% |
| Editas Medicine, Inc. | -87.11 Million USD | 5566.275% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 62.956% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | -126.982% |
| Myriad Genetics, Inc. | 88.1 Million USD | -5305.221% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -2585.843% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 14303.478% |
| Verastem, Inc. | -37.27 Million USD | 12874.29% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 42.174% |
| Waters Corporation | 1.96 Billion USD | -142.905% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 82.258% |
| Biogen Inc. | 6.28 Billion USD | 24.272% |
| Nektar Therapeutics | 210.24 Million USD | -2165.03% |
| Perrigo Company plc | 3.32 Billion USD | -43.343% |
| Dynavax Technologies Corporation | 106.63 Million USD | -4365.701% |
| Illumina, Inc. | 1.21 Billion USD | -292.257% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -68240.242% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 4281.301% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -3182.417% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -66158.522% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -1157.3% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 67170.423% |
| Evolus, Inc. | 63.7 Million USD | -7374.728% |
| Adicet Bio, Inc. | -142 Million USD | 3453.332% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 13038.811% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 17671.956% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -938.154% |
| FibroGen, Inc. | 56.76 Million USD | -8288.677% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -315.895% |
| OPKO Health, Inc. | 230.68 Million USD | -1964.305% |
| Homology Medicines, Inc. | 18.43 Million USD | -25728.497% |
| Geron Corporation | 14.76 Million USD | -32160.687% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -200.38% |
| Exelixis, Inc. | -73.05 Million USD | 6618.823% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 8876.909% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 3253.141% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 4374.609% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 2483.133% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 47384.282% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 149.791% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 32779.111% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -351.686% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -391.75% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 3616.987% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -244.853% |
| Blueprint Medicines Corporation | 702.83 Million USD | -577.541% |
| Insmed Incorporated | 721.62 Million USD | -559.904% |
| TG Therapeutics, Inc. | 17.86 Million USD | -26559.948% |
| Incyte Corporation | -3.17 Billion USD | 249.98% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -521.833% |